Clinical Monograph: Adderall (Mixed Amphetamine Salts)

1. Classification and Chemical Overview

Adderall is a combination preparation composed of equal parts of four amphetamine salts: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate. This formulation yields a 3:1 ratio of the dextro- isomer to the levo- isomer. Under the Anatomical Therapeutic Chemical (ATC) system, amphetamine combinations are indexed under N06BA01.

• Product Context: Available in immediate-release (IR) tablets (e.g., 5 mg, 10 mg, 20 mg, 30 mg) and extended-release (XR) capsules designed for once-daily dosing.

• Controlled Status: Strictly regulated as a Prescription Only Medicine (POM) and a Schedule II Controlled Substance (or Class B / Schedule 2 Controlled Drug internationally) due to its extremely high potential for abuse, psychological dependence, and misuse liability.

2. Mechanism of Action and Pharmacodynamics

Amphetamines exert their primary stimulant and therapeutic effects by enhancing monoamine neurotransmission in the central nervous system:

• Presynaptic Release: Amphetamines enter presynaptic neurons via active transport (such as monoamine transporters), where they interact with trace amine-associated receptor 1 (TAAR1) and vesicular monoamine transporter 2 (VMAT2) to trigger the robust, non-exocytotic release of dopamine (DA) and norepinephrine (NE) from storage vesicles into the cytoplasm and synaptic cleft.

• Reuptake Inhibition: Binds to and competitively inhibits monoamine transporters (DAT and NET), preventing the reuptake of dopamine and norepinephrine.

• Pharmacodynamic Profile: Amplified catecholamine signaling within the prefrontal cortex and striatum improves sustained attention, executive function, impulse control, and behavioral inhibition in ADHD, while promoting wakefulness in narcolepsy.

3. Approved Clinical Indications and Dosing Scope

Licensing for Adderall includes:

• Attention Deficit Hyperactivity Disorder (ADHD): Treatment of ADHD in children (aged 3 years and older), adolescents, and adults as part of a comprehensive management program.

• Narcolepsy: Management of excessive daytime sleepiness associated with narcolepsy in patients aged 6 years and older.

Dosing & Administration Regimen:

• Immediate-Release (IR) vs. Extended-Release (XR): IR formulations are typically administered 2 to 3 times daily, spaced 4 to 6 hours apart. XR formulations are administered once daily in the morning.

• Starting Doses & Titration: Therapy is initiated at low doses (e.g., 5 mg once or twice daily for IR) and titrated upward gradually by small increments at weekly intervals based on clinical response and tolerability.

• Administration Precautions: Avoid late afternoon or evening administration with all formulations to prevent severe, prolonged insomnia. XR capsules may be swallowed whole or opened and sprinkled over applesauce for immediate consumption (do not crush or chew the bead matrix).

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Readily and completely absorbed from the gastrointestinal tract. Peak plasma concentrations are achieved within 3 hours for immediate-release tablets and 7 hours for extended-release capsules.

• Distribution: Readily crosses the blood-brain barrier and placenta; distributes extensively into body tissues. Plasma protein binding is low (~15% to 20%).

• Biotransformation: Metabolized in the liver primarily via aromatic and aliphatic hydroxylation, $N$-dealkylation, and deamination. CYP2D6 is involved in the formation of active hydroxylated metabolites (such as 4-hydroxyamphetamine and norephedrine).

• Elimination: Excreted predominantly via the kidneys in urine as unchanged parent drug and metabolites. Urinary elimination is heavily dependent on urinary pH: acidic urine accelerates renal clearance, whereas alkaline urine prolongs the elimination half-life. The terminal elimination half-life averages 10 to 13 hours.

5. Physiological Effects and Adverse Event Spectrum

Adderall stimulates the sympathetic nervous system, increasing heart rate, elevating blood pressure, dilating pupils, and suppressing appetite.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Decreased appetite, weight loss, insomnia, dry mouth, headache, emotional lability, tachycardia, abdominal pain, nervousness.

• Common ($\ge 1/100$ to $<1/10$): Palpitations, anxiety, restlessness, dizziness, tremor, dysgeusia, constipation, diarrhea, hyperhidrosis, bruxism, growth velocity suppression in pediatric patients.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Hypertension, vision blurred, rash, libido changes, psychomotor hyperactivity, depression.

• Rare / Severe (<1/1,000): Psychotic episodes, visual and tactile hallucinations, cardiomyopathy (with chronic high-dose misuse), seizures, cerebrovascular accidents, myocardial infarction, sudden cardiac death in vulnerable individuals.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindications

• Known hypersensitivity to amphetamine products or formulation excipients.

• Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their cessation (risk of life-threatening hypertensive crisis).

• Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, or structural cardiac abnormalities.

• Hyperthyroidism, glaucoma, or history of advanced agitated states.

• History of active drug abuse or substance use disorder.

Key Drug Interactions

• Monoamine Oxidase Inhibitors (MAOIs): Concurrent administration triggers severe hypertensive crises and dangerous hyperthermia.

• Serotonergic Agents (SSRIs, SNRIs): Co-administration elevates the risk of serotonin syndrome due to enhanced monoaminergic activity.

• Acidifying & Alkalinizing Agents: Gastrointestinal and urinary acidifiers (e.g., ascorbic acid, ammonium chloride) accelerate renal clearance and reduce efficacy, whereas urinary alkalinizers (e.g., sodium bicarbonate) prolong half-life and increase systemic exposure.

• Antihypertensives: Stimulants can antagonize the blood pressure-lowering effects of antihypertensive medications.

Clinical Precautions and Monitoring

• Boxed Warning (Abuse, Misuse, and Dependence): CNS stimulants have a high potential for abuse and dependence. Assess clinical risk prior to prescribing and monitor patients regularly for signs of misuse, diversion, or dose escalation.

• Cardiovascular Evaluation: Evaluate cardiac status prior to treatment. Monitor blood pressure and heart rate regularly during therapy, particularly in patients with underlying cardiovascular conditions.

• Growth Suppression: Long-term stimulant use in pediatric patients can be associated with temporary suppression of weight gain and linear growth velocity; monitor height and weight periodically.